RNA Outsourcing Resources

31. New Perspectives On Accelerating Genetic Nanomedicines Through The Regulatory Pathway 3/1/2024

    Discover how regulatory bodies are adopting a risk-based approach to address the unique challenges of genetic nanomedicines, and stakeholder engagement is essential.

32. Learn How Compliance-Ready LC-MS Workflows for Oligonucleotides Can Expand your Analytical Services Portfolio 2/22/2022

    CMO invests in solution to ensure data integrity and meet regulatory requirements as they expand their oligonucleotide manufacturing and analysis services.

33. Pre-Banking And Avoiding Manufacturing Challenges For GMP Plasmids Containing Unstable Sequence Regions 4/21/2021

    Ensuring consistent replication and proper retention of plasmid DNA sequence is vital to the economics and efficiency in generating starting materials used for production of AAV delivered gene therapy and mRNA vaccines and therapeutics.

34. Contract Design And Development Vs. In-House: Finding The Best Fit 11/18/2024

    Outsourcing medical device R&D to Contract Development Organizations (CDOs) aids innovation, scales resources, and overcomes constraints. Strategic evaluation ensures successful partnerships.

35. Identifying Sustainable Pathways Toward Oligonucleotide Therapeutics

    What sustainable manufacturing processes best address Oligonucleotide environmental impact while maintaining scalability?

36. Supercharge Your Supply Chain: Harness AI To Gain Competitive Advantage

    The success of CGTs hinges upon adherence to specific logistics protocols. Learn how the integration of AI in the pharma supply chain is poised to enhance visibility, efficiency, and compliance.

37. Navigating Challenges In Progressing Breakthrough RNA Therapeutics 5/14/2024

    RNA therapeutics hold immense promise for precision treatment, but their development faces challenges. A CDMO with adaptable platforms and flexible timelines can help reduce time and costs.

38. Getting CMC Right For Emerging Technologies 12/20/2023

    Establishing a chemistry, manufacturing, and controls strategy that proves a clinical program is tightly controlled and can address risk is critical to avoiding the pitfalls that stall many promising therapeutics.

39. When Is A New Biologic Ready For GMP Production? 1/17/2023

    While there are differences by modality in DNA, RNA, and protein, find general recommendations on questions to prepare for and steps to consider when preparing to move to clinic.

40. Pioneering The Future Of Pharmaceutical Supply Chains

    Drive the efficiency and resiliency of supply chains by integrating automation, AI, and effective communication, ensuring the successful distribution of lifesaving medicinal products.